Close

Barclays Starts CRISPR Therapeutics (CRSP) at Overweight

Go back to Barclays Starts CRISPR Therapeutics (CRSP) at Overweight

Citi Starts CRISPR Therapeutics (CRSP) at Neutral

November 15, 2016 7:41 AM EST

Citi initiated coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Neutral rating and a price target of $19.00.

For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.

Shares of CRISPR Therapeutics closed at $17.60 yesterday.

... More

Guggenheim Starts CRISPR Therapeutics (CRSP) at Buy

November 14, 2016 7:56 AM EST

Guggenheim initiated coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Buy rating and a price target of $30.00.

For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.

Shares of CRISPR Therapeutics closed at $17.50 yesterday.

... More